Literature DB >> 23452312

Novel therapies for the management of type 2 diabetes mellitus: part 1. pramlintide and bromocriptine-QR.

George Grunberger1.   

Abstract

Several classes of antidiabetic agents have been introduced into the market place over the past dozen years. As our understanding of the underlying pathophysiology of type 2 diabetes has advanced, attempts have been made to address these defects specifically. This brief review focuses on our experience with two such pharmacological approaches: (i) a synthetic amylin analog addressing amylin deficiency; and (ii) a dopaminergic agonist, focused on enhancing the lowered dopaminergic tone in patients with type 2 diabetes. Importantly, the use of these agents is not associated with hypoglycemia or weight gain.
© 2013 Wiley Publishing Asia Pty Ltd and Ruijin Hospital, Shanghai Jiaotong University School of Medicine.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23452312     DOI： 10.1111/1753-0407.12034

Source DB:  PubMed          Journal:  J Diabetes        ISSN： 1753-0407            Impact factor:   4.006


  9 in total

Review 1.  Dopamine receptors - IUPHAR Review 13.

Authors:  Jean-Martin Beaulieu; Stefano Espinoza; Raul R Gainetdinov
Journal:  Br J Pharmacol       Date:  2015-01       Impact factor: 8.739

2.  Phosphatidic acid: a new therapeutic lead to suppress hepatic glucose production.

Authors:  Anil K Agarwal; Shireesha Sankella
Journal:  Diabetes Manag (Lond)       Date:  2014

3.  Reduced insulin sensitivity is related to less endogenous dopamine at D2/3 receptors in the ventral striatum of healthy nonobese humans.

Authors:  Fernando Caravaggio; Carol Borlido; Margaret Hahn; Zhe Feng; Gagan Fervaha; Philip Gerretsen; Shinichiro Nakajima; Eric Plitman; Jun Ku Chung; Yusuke Iwata; Alan Wilson; Gary Remington; Ariel Graff-Guerrero
Journal:  Int J Neuropsychopharmacol       Date:  2015-02-25       Impact factor: 5.176

Review 4.  Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases.

Authors:  Alexander O Shpakov; Kira V Derkach; Lev M Berstein
Journal:  Future Sci OA       Date:  2015-11-01

Review 5.  Chemical Glycosylation and Its Application to Glucose Homeostasis-Regulating Peptides.

Authors:  Chaitra Chandrashekar; Mohammed Akhter Hossain; John D Wade
Journal:  Front Chem       Date:  2021-04-12       Impact factor: 5.221

Review 6.  Dissecting Sex-Related Cognition between Alzheimer's Disease and Diabetes: From Molecular Mechanisms to Potential Therapeutic Strategies.

Authors:  Ghulam Md Ashraf; Mahmoud Ahmed Ebada; Mohd Suhail; Ashraf Ali; Md Sahab Uddin; Anwar L Bilgrami; Asma Perveen; Amjad Husain; Mohd Tarique; Abdul Hafeez; Athanasios Alexiou; Ausaf Ahmad; Rajnish Kumar; Naheed Banu; Agnieszka Najda; Amany A Sayed; Ghadeer M Albadrani; Mohamed M Abdel-Daim; Ilaria Peluso; George E Barreto
Journal:  Oxid Med Cell Longev       Date:  2021-03-05       Impact factor: 6.543

7.  A co-formulation of supramolecularly stabilized insulin and pramlintide enhances mealtime glucagon suppression in diabetic pigs.

Authors:  Caitlin L Maikawa; Anton A A Smith; Lei Zou; Gillie A Roth; Emily C Gale; Lyndsay M Stapleton; Sam W Baker; Joseph L Mann; Anthony C Yu; Santiago Correa; Abigail K Grosskopf; Celine S Liong; Catherine M Meis; Doreen Chan; Megan Troxell; David M Maahs; Bruce A Buckingham; Matthew J Webber; Eric A Appel
Journal:  Nat Biomed Eng       Date:  2020-05-11       Impact factor: 25.671

Review 8.  Role of ketone bodies in diabetes-induced dementia: sirtuins, insulin resistance, synaptic plasticity, mitochondrial dysfunction, and neurotransmitter.

Authors:  Ji Yeon Chung; Oh Yoen Kim; Juhyun Song
Journal:  Nutr Rev       Date:  2022-03-10       Impact factor: 7.110

Review 9.  Hypothyroidism and Diabetes-Related Dementia: Focused on Neuronal Dysfunction, Insulin Resistance, and Dyslipidemia.

Authors:  Hee Kyung Kim; Juhyun Song
Journal:  Int J Mol Sci       Date:  2022-03-10       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.